<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHOCARBAMOL</span><br/>(meth-oh-kar'ba-mole)<br/><span class="topboxtradename">Marbaxin, </span><span class="topboxtradename">Robaxin<br/></span><b>Classifications:</b> <span class="classification">somatic nervous system agent; skeletal muscle relaxant; central-acting</span><br/><b>Prototype: </b>Cyclobenzaprine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 750 mg tablet; 100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Similar to cyclobenzaprine, but it produces higher plasma levels more rapidly and for longer periods. Exerts skeletal muscle
         relaxant action by depressing multisynaptic pathways in the spinal cord and possibly by sedative effect.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>No direct action on skeletal muscles; just on multisynaptic pathways in spinal cord that control muscular spasm.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to physical therapy and other measures in management of discomfort associated with acute musculoskeletal disorders.
         Also used intravenously as adjunct in management of neuromuscular manifestations of tetanus.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Comatose states; CNS depression; acidosis, kidney dysfunction (injectable methocarbamol contains polyethylene glycol 300 in
         vehicle, which may cause urea retention and acidotic problems); pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Epilepsy; older adults; females of childbearing age; renal disease, renal failure, renal impairment, seizure disorder; lactation,
         children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Musculoskeletal Disorders</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.5 g q.i.d. for 23 d, then 44.5 g/d in 36 divided doses <span class="rdroute">IM</span> 0.51 g q8h <span class="rdroute">IV</span> 13 g/d in divided doses (max: rate of 300 mg/min)<br/><br/><span class="indicationtitle">Tetanus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Up to 24 g/d in divided doses crushed and suspended in saline, flushed down a nasogastric tube <span class="rdroute">IV</span> 12 g/d directly into IV tubing (max: rate of 300 mg/min), may be repeated q6h until nasogastric tube is possible<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 15 mg/kg repeated q6h as needed up to 1.8 g/m<sup>2</sup>/d for 3 consecutive d if necessary<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Do not exceed IM dose of 5 mL (0.5 g) into each gluteal region. Insert needle deep and carefully aspirate. Inject drug slowly.
            Rotate injection sites and observe daily for evidence of irritation.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May be given undiluted or diluted in up to 250 mL of NS or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 300 mg or fraction thereof over 1 min or longer.  
               </p>
<ul>
<li>Keep patient recumbent during and for at least 15 min after IV injection in order to reduce possibility of orthostatic hypotension
                     and other adverse reactions.
                  </li>
<li>Monitor vital signs and IV flow rate. </li>
<li>Take care to avoid extravasation of IV solution, which may result in thrombophlebitis and sloughing.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fever, <span class="speceff-life">anaphylactic reaction</span>, flushing, syncope, convulsions. <span class="typehead">Skin:</span> Urticaria, pruritus, rash, thrombophlebitis, pain, sloughing (with extravasation). <span class="typehead">Special Senses:</span> Conjunctivitis, blurred vision, nasal congestion. <span class="typehead">CNS:</span> <span class="speceff-common">Drowsiness, dizziness, light-headedness,</span> headache. <span class="typehead">CV:</span> Hypotension, bradycardia. <span class="typehead">GI:</span> Nausea, metallic taste. <span class="typehead">Hematologic:</span> Slight reduction of white cell count with prolonged therapy. <span class="typehead"> Renal:</span> Polyethylene glycol in the injection may increase preexisting acidosis and urea retention in patients with renal impairment. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Methocarbamol may cause false increases in <span class="alt">urinary 5-HIAA</span> (with <span class="alt">nitrosonaphthol reagent</span>) and <span class="alt">VMA</span> <b></b> <span class="alt">(Gitlow method)</span> <b>.</b>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> enhance CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 30 min. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain periodic WBC counts during prolonged therapy.</li>
<li>Monitor vital signs closely during IV infusion.</li>
<li>Supervise ambulation following parenteral administration.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Make position changes slowly, particularly from lying down to upright position; dangle legs before standing.</li>
<li>Be aware that adverse reactions after oral administration are usually mild and transient and subside with dosage reduction.
            Use caution regarding drowsiness and dizziness. Avoid activities requiring mental alertness and physical coordination until
            response to drug is known.
         </li>
<li>Urine may darken to brown, black, or green on standing.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>